Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value per share
Symbol
TERN on Nasdaq
Shares outstanding
87,692,308
Price per share
$40.40
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
88,633,014
Total reported value
$665,699,966
% of total 13F portfolios
0%
Share change
+5,945,163
Value change
+$50,616,488
Number of holders
139
Price from insider filings
$40.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Soleus Capital Master Fund, L.P. 9.6% $18,727,750 8,142,500 Soleus Capital Master Fund, L.P. 31 Dec 2024
Deep Track Capital, LP 8.6% +36% $52,989,650 +$13,563,385 7,495,000 +34% Deep Track Capital, LP 30 Jun 2025
MORGAN STANLEY 8.1% $16,329,894 7,099,954 Morgan Stanley 31 Mar 2025
BlackRock, Inc. 6.8% $13,210,009 5,743,482 BlackRock, Inc. 31 Dec 2024
Commodore Capital LP 6.5% +24% $42,807,000 +$7,885,500 5,700,000 +23% Commodore Capital LP 30 Sep 2025
VANGUARD GROUP INC 5.2% $34,244,977 4,559,917 The Vanguard Group 30 Sep 2025
Schonfeld Strategic Advisors LLC 4.9% -20% $9,901,969 -$2,137,399 4,305,204 -18% Schonfeld Strategic Advisors LLC 31 Mar 2025
ORBIMED ADVISORS LLC 4.8% $31,842,911 4,240,068 ORBIMED ADVISORS LLC 03 Nov 2025
CITADEL ADVISORS LLC 4.1% $7,970,206 3,465,307 Kenneth Griffin 31 Dec 2024

As of 30 Sep 2025, 139 institutional investors reported holding 88,633,014 shares of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN). This represents 101% of the company’s total 87,692,308 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Soleus Capital Management, L.P. 9.3% 8,127,100 -0.49% 3.3% $61,034,521
MORGAN STANLEY 8.7% 7,589,095 +4.6% 0% $56,994,103
ORBIMED ADVISORS LLC 8.6% 7,562,971 0% 1.4% $56,797,912
Deep Track Capital, LP 8.5% 7,495,000 0% 1.6% $56,287,450
Vivo Capital, LLC 7.9% 6,895,746 0% 4.2% $51,787,052
Commodore Capital LP 6.5% 5,700,000 2.1% $42,807,000
BlackRock, Inc. 6.3% 5,551,308 +1.5% 0% $41,690,324
VANGUARD GROUP INC 5.2% 4,559,917 +5.9% 0% $34,244,976
ADAGE CAPITAL PARTNERS GP, L.L.C. 4.5% 3,939,000 +208% 0.05% $29,581,890
Candriam S.C.A. 2.7% 2,368,235 0% 0.09% $17,785,445
ACORN CAPITAL ADVISORS, LLC 2.2% 1,971,264 0% 7.5% $14,804,193
Schonfeld Strategic Advisors LLC 2.2% 1,891,925 -38% 0.1% $14,208,354
GEODE CAPITAL MANAGEMENT, LLC 2% 1,714,552 +5% 0% $12,879,165
STATE STREET CORP 1.8% 1,605,693 +17% 0% $12,058,754
CITADEL ADVISORS LLC 1.8% 1,589,334 -59% 0.01% $11,935,898
Nuveen, LLC 1.7% 1,473,371 +25% 0% $11,065,016
DIMENSIONAL FUND ADVISORS LP 1.7% 1,456,401 -12% 0% $10,938,939
FRANKLIN RESOURCES INC 1.5% 1,277,463 +0.01% 0% $9,593,747
Pictet Asset Management Holding SA 1.3% 1,104,204 0.01% $8,292,572
UBS Group AG 1.1% 972,772 -17% 0% $7,305,517
Integral Health Asset Management, LLC 1.1% 950,000 +36% 0.52% $7,134,500
MILLENNIUM MANAGEMENT LLC 1.1% 941,584 -5.5% 0.01% $7,071,296
Parkman Healthcare Partners LLC 1.1% 934,760 +14% 0.77% $7,020,048
SUPERSTRING CAPITAL MANAGEMENT LP 0.9% 789,646 -39% 5.8% $5,930,241
BANK OF AMERICA CORP /DE/ 0.8% 704,773 +43% 0% $5,292,844

Institutional Holders of Terns Pharmaceuticals, Inc. - Common Stock, $0.0001 par value per share (TERN) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 234,896 $9,489,175 +$1,579,592 $40.40 13
2025 Q3 88,633,014 $665,699,966 +$50,616,488 $7.51 139
2025 Q2 83,108,168 $309,995,477 +$2,354,806 $3.73 126
2025 Q1 83,089,113 $229,385,781 -$20,904,215 $2.76 134
2024 Q4 86,124,931 $477,116,608 +$3,705,907 $5.54 155
2024 Q3 79,491,087 $663,003,221 +$119,235,282 $8.34 154
2024 Q2 65,586,958 $446,681,890 +$18,084,213 $6.81 124
2024 Q1 63,102,304 $413,941,619 +$5,035,353 $6.56 111
2023 Q4 17,879 $116,035 $6.49 1
2023 Q3 61,282,212 $308,250,920 +$7,252,748 $5.03 91
2023 Q2 57,551,829 $503,579,772 +$30,407,534 $8.75 101
2023 Q1 53,226,532 $630,202,113 +$46,060,367 $11.84 79
2022 Q4 49,723,642 $506,191,882 +$196,797,561 $10.18 64
2022 Q3 30,203,299 $177,898,000 +$107,047,630 $5.89 43
2022 Q2 14,674,771 $36,391,000 -$5,896,641 $2.48 34
2022 Q1 16,798,103 $49,892,000 -$1,395,737 $2.97 42
2021 Q4 16,503,387 $116,663,000 -$4,532,028 $7.07 37
2021 Q3 16,725,042 $174,277,000 -$738,010 $10.42 33
2021 Q2 16,621,277 $203,778,000 -$23,567,604 $12.26 36
2021 Q1 17,905,568 $393,655,000 +$393,105,179 $22.00 42